(LYEL) Lyell Immunopharma - Ratings and Ratios

Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a clinical-stage biotechnology company specializing in the development of innovative T cell therapies for solid tumor treatments. The company leverages proprietary ex vivo genetic and epigenetic reprogramming technologies to enhance T cell functionality and persistence. Its platform includes c Jun overexpression to mitigate T cell exhaustion and NR4A3 gene knockout to improve T cell resilience. Additionally, Lyell employs Epi R and Stim R technologies to generate T cells with enhanced stemness and synthetic cell mimetics for sustained anti-tumor activity.

The companys pipeline includes LYL797, a ROR1-targeting CAR T cell product candidate currently in Phase 1 clinical trials for solid tumors. LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocyte (TIL) product, is also in Phase 1 trials for multiple solid tumor indications. Preclinical development includes LYL119, a next-generation ROR1 CAR T-cell product designed for enhanced cytotoxicity, and a second-generation TIL product aimed at improving efficacy in solid tumor treatments.

Lyell Immunopharma, founded in 2018 and headquartered in South San Francisco, California, focuses on addressing the limitations of current cell therapies through its cutting-edge reprogramming approaches. For more information, visit their website at https://lyell.com.

3-Month Forecast: Based on the provided data, Lyell Immunopharmas stock (NASDAQ: LYEL) is expected to experience volatility due to its micro-cap nature and clinical-stage risks. Technically, the stock is trading below its 200-day SMA of $1.29, indicating potential long-term bearish pressure. However, the recent price of $0.66 is slightly above its 20-day and 50-day SMAs, suggesting short-term stability. The ATR of $0.05 reflects low volatility, which may persist in the near term. Fundamentally, the companys high P/S ratio of 3296.33 highlights market expectations for growth, though the negative RoE of -38.44% and low P/B ratio of 0.39 signal financial challenges. Overall, the stock may see a modest recovery in the short term but faces longer-term headwinds due to its developmental stage and financial metrics.